Investigational drug · Phase 2
DONQ52
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "DONQ52"
First trial start
2025
Dec 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DONQ52", any sponsor or status.
Conditions studied
As listed on its trial records.
- Celiac Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DONQ52" as an intervention, largest first.
- Study of DONQ52 in Active Celiac DiseaseRecruiting
Chugai PharmaceuticalIndustry
NCT07239336 · 92 participants (planned) · Start Dec 16, 2025 · Primary completion Jun 15, 2027
Drug: Placebo DONQ52; DONQ52 · For: Celiac Disease
Sites: Anniston, Alabama; Homewood, Alabama; Mobile, Alabama · 74 sites in all
Chugai PharmaceuticalIndustry
NCT05425446 · 56 participants · Start Sep 19, 2022 · Primary completion Aug 9, 2024
Drug: DONQ52; Placebo · For: Celiac Disease
Sites: Anniston, Alabama; Denver, Colorado; Jacksonville, Florida · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease.
Hardy MY, Henneken LM, Russell AK, et al. · Clin Immunol 2024
- Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.
Okura Y, Ikawa-Teranishi Y, Mizoroki A, et al. · Nat Commun 2023
Also in development for Celiac Disease
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- Larazotide AcetatePhase 31 trial
Interlude Biopharma Co. · Celiac Disease, Celiac Disease in Adolescents
- FB102Phase 21 trial
Forte Biosciences, Inc. · Celiac Disease
- KAN-101Phase 21 trial
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA · Celiac Disease, Coeliac Disease
- TAK-101Phase 21 trial
Takeda · Celiac Disease
- ZED1227Phase 21 trial
Dr. Falk Pharma GmbH · Celiac Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.